Beigene Insider Sold Shares Worth $7,370,515, According to a Recent SEC Filing
Indaptus Therapeutics Provides 2025 Outlook, Launching Decoy20 Combination Cohort With BeiGene's Tislelizumab, Expanding Clinical Sites Beyond 8, Updating Higher Dose Cohort, First Patient Dosed In Combination, Focus On Cancer Challenges
BeiGene Issues Overseas Regulatory Announcement on Form 10-K/A Amendment
10-K/A: Annual report (Amendment)
BEIGENE (06160.HK) issued 0.5429 million shares due to the Director exercising stock options.
Gelonghui reported on January 8 that BEIGENE (06160.HK) announced the issuance of 0.5429 million shares of common stock due to a Director exercising stock options on January 8, 2025.
MAIA Biotechnology Shares Rise After Supply Agreement With BeiGene
